Statera Biopharma, Inc. (NASDAQ:STAB) Short Interest Up 444.2% in October
Statera Biopharma, Inc. (NASDAQ:STAB) Short Interest Up 444.2% in October
Statera Biopharma, Inc. (NASDAQ:STAB – Get Rating) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 2,390,000 shares, an increase of 444.2% from the September 30th total of 439,200 shares. Currently, 5.8% of the shares of the stock are sold short. Based on an average daily volume of 2,740,000 shares, the days-to-cover ratio is currently 0.9 days.
斯塔特拉生物製藥公司 (納斯達克代碼：STAB-獲取評級) 是 10 月份短期利息大幅增加的目標。截至十月十五日，公司短倉合計 2,390,000 股，較九月三十日合計 439,200 股增加 444.2%。目前，股票 5.8％ 的股票賣空。以平均每日成交量 2,740,000 股計算，目前的日對發行額比率為 0.9 天。
Statera Biopharma Stock Performance
斯泰特拉生物製藥股票表現
STAB remained flat at $0.15 during midday trading on Friday. 516,431 shares of the company's stock were exchanged, compared to its average volume of 3,652,617. Statera Biopharma has a one year low of $0.11 and a one year high of $4.18. The company's fifty day moving average price is $0.17 and its 200-day moving average price is $0.22.
據報道，該公司的股票交易額為 516,431 股，該公司的平均成交量為 3,652,617 股。斯塔特拉生物製藥有 0.11 美元的一年低點和 4.18 美元的一年高點。該公司的 50 天移動平均價格為 0.17 美元，其 200 天移動平均價格為 0.22 美元。
Institutional Trading of Statera Biopharma
國泰生物製藥股份有限公司機構交易
Large investors have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. grew its position in shares of Statera Biopharma by 275.9% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 112,250 shares of the company's stock valued at $35,000 after purchasing an additional 82,391 shares during the last quarter. UBS Group AG acquired a new stake in shares of Statera Biopharma in the first quarter valued at approximately $37,000. Virtu Financial LLC grew its position in shares of Statera Biopharma by 409.2% in the first quarter. Virtu Financial LLC now owns 157,678 shares of the company's stock valued at $50,000 after purchasing an additional 126,715 shares during the last quarter. Northern Trust Corp grew its position in shares of Statera Biopharma by 335.9% in the first quarter. Northern Trust Corp now owns 171,110 shares of the company's stock valued at $54,000 after purchasing an additional 131,855 shares during the last quarter. Finally, Empery Asset Management LP purchased a new position in shares of Statera Biopharma during the first quarter valued at approximately $105,000. 8.40% of the stock is currently owned by institutional investors and hedge funds.
大型投資者最近修改了他們對該業務的持有量。雷蒙德詹姆斯金融服務顧問公司在第一季度將其在斯塔泰拉生物製藥股份中的地位增長了 275.9%。雷蒙德詹姆斯金融服務顧問公司現在擁有該公司股票的 112,250 股股票，價值 35,000 美元，在上個季度額外購買了 82,391 股股票後。瑞銀集團在第一季度收購了 Statera 生物製藥股份的新股份，價值約 37,000 美元。在第一季度，Virtu 金融有限責任公司在斯塔特拉生物製藥股份的地位增長了 409.2%。在上一季度，維圖金融有限公司現在擁有 157,678 股公司股票，價值 50,000 美元。北方信託公司在第一季度增加了 Statera 生物製藥股份的地位 335.9%。北方信託公司現在擁有 171,110 股該公司股票，價值 54,000 美元，在最後一季度額外購買 131,855 股股票後，該公司股票價值 54,000 美元。最後，英皇資產管理有限公司在第一季度購買了 Statera 生物製藥股份的新頭寸，價值約 105,000 美元。目前該股票的 8.40％ 由機構投資者和對沖基金持有。
Statera Biopharma Company Profile
斯泰拉生物製藥公司簡介
Statera BioPharma, Inc, a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.
Statera BioPharma, Inc 是一家臨床階段的生物製藥公司，基於專有平台，旨在重新平衡人體免疫系統並恢復體內平衡，開發針對自身免疫性、中性粒細胞減少/貧血、新興病毒和癌症的新型免疫療法。該公司正在開發旨在直接引起患者內部抗原特異性殺手 T 細胞和抗體的反應的療法，從而激活對自身免疫、炎症、傳染性疾病和癌症的必要免疫防禦。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Statera Biopharma (STAB)
- McDonald's Stock Sizzles, but Will it Hit a New All-Time High?
- Chevron Gushes More Profits; Is it Time for Investors to Buy?
- Can Comcast Monetize Existing Users for Streaming Success?
- Why is Amazon Stock Falling? Is the Sell-Off Overdone?
- Apple Inc. Stock Q4 Results Beat Negative Outlook, Stock Rises
- 中職》中華職棒大聯賽第一名、第一名、第一名、第一名、第一名、第一名、第一名
- 麥當勞股票嘶嘶聲，但它會創下歷史新高嗎？
- 雪佛龍湧出更多利潤；投資者是時候購買了嗎？
- 康卡斯特可以通過現有用戶獲利以獲得流媒體成功嗎？
- 為什麼是亞馬遜股票下跌？拋售是否過度？
- 蘋果公司第四季度股票結果擊敗負面前景，股市上漲
Receive News & Ratings for Statera Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Statera Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Statera 生物製藥日報的新聞和評級 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Statera 生物製藥和相關公司的最新新聞和分析師評分的簡明每日摘要。
譯文內容由第三人軟體翻譯。